– USA, MA – Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, announced today the appointment of Greg Norden to the company’s Board of Directors.
“Greg is an outstanding leader in our industry, and I am delighted to welcome him to our Board,” said Manos Perros, Chief Executive Officer of Entasis. “Greg joins our team during an exciting time for the company, with our second flagship program, ETX2514, entering the clinic. Greg brings a wealth of industry knowledge and expertise which will be an invaluable asset to Entasis as we advance our programs.”
Mr. Norden brings more than 20 years of leadership and financial management experience in global healthcare and pharmaceuticals. He is currently the Managing Director of G9 Capital Group, LLC, which invests in early stage ventures and provides corporate finance advisory services. From 1989 to 2010, Mr. Norden held various senior positions with Wyeth/American Home Products, most recently as Wyeth’s Senior Vice President and Chief Financial Officer. Prior to this role, Mr. Norden was Executive Vice President and Chief Financial Officer of Wyeth Pharmaceuticals. Mr. Norden began his career at Arthur Andersen & Co. and served as an Audit Manager.
“Greg’s financial expertise and leadership experience in the pharmaceutical industry will further strengthen our Board’s broad skillset,” said Nick Galakatos, Managing Director of Clarus Ventures and Chairman of the Board of Entasis. “I am confident that Greg will make important contributions to the Entasis Board, which will translate to a positive impact for the company.”
Mr. Norden serves on several Boards including: NanoString, a provider of life science tools for translational research and molecular diagnostic products; Royalty Pharma, a leader in the acquisition of revenue-producing intellectual property; Univision, the leading media company serving Hispanic America; and Zoetis, the leading animal health company.
“It’s a pivotal time for antibacterials and Entasis has built an innovative pipeline that’s well positioned to address the growing unmet medical need of drug-resistant bacterial infections,” said Norden. “I admire the company’s achievements since its inception in 2015 and I very much look forward to joining the current Board of Directors in developing Entasis into the next leader in infectious diseases.”
About Entasis Therapeutics Inc.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of fundamentally innovative clinical and preclinical anti-infective programs is designed to revolutionize the way physicians treat serious bacterial diseases.
For more information : http://www.entasistx.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.